Abstract
Background In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods Blood sampling was performed before PPCI. Consecutive patients with (n=24) or without (n=24) evidence of angiographic no-reflow after PPCI were enrolled. Angiographic no-reflow was defined as Thrombolysis in Myocardial Infarction (TIMI) flow ≤2 or as TIMI flow=3 but with myocardial blush grade -1, P=0·001, and 4·0 (0·6-7·1) vs. 9·3 (1·0-12·6) mIUmL -1, P=0·01, respectively]. At multivariable analysis, decreasing EPO tertiles and left anterior descending as the infarct-related artery were the only factors that predicted both angiographic and ECG no-reflow (P=0·017 and P=0·02 for EPO; P0·05 for left anterior descending artery, respectively). Conclusions We found an independent, graded, inverse relation between endogenous EPO levels and angiographic and ECG no-reflow following PPCI. In animal models of ischaemia, EPO has been found to be protective. In humans, endogenous EPO may contribute to offset the mechanisms responsible for no-reflow.
| Original language | English |
|---|---|
| Pages (from-to) | 1210-1219 |
| Number of pages | 10 |
| Journal | European Journal of Clinical Investigation |
| Volume | 41 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2011 |
Fingerprint
Keywords
- Acute myocardial infarction
- Erythropoietin
- No-reflow
- Primary PCI
ASJC Scopus subject areas
- Medicine(all)
- Clinical Biochemistry
- Biochemistry
Cite this
Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. / Niccoli, Giampaolo; Andreotti, Felicita; Marzo, Francesca; Cecchetti, Silvia; Santucci, Eleonora; D'Amario, Domenico; Pafundi, Teodosio; Cosentino, Nicola; Crea, Filippo.
In: European Journal of Clinical Investigation, Vol. 41, No. 11, 11.2011, p. 1210-1219.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction
AU - Niccoli, Giampaolo
AU - Andreotti, Felicita
AU - Marzo, Francesca
AU - Cecchetti, Silvia
AU - Santucci, Eleonora
AU - D'Amario, Domenico
AU - Pafundi, Teodosio
AU - Cosentino, Nicola
AU - Crea, Filippo
PY - 2011/11
Y1 - 2011/11
N2 - Background In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods Blood sampling was performed before PPCI. Consecutive patients with (n=24) or without (n=24) evidence of angiographic no-reflow after PPCI were enrolled. Angiographic no-reflow was defined as Thrombolysis in Myocardial Infarction (TIMI) flow ≤2 or as TIMI flow=3 but with myocardial blush grade -1, P=0·001, and 4·0 (0·6-7·1) vs. 9·3 (1·0-12·6) mIUmL -1, P=0·01, respectively]. At multivariable analysis, decreasing EPO tertiles and left anterior descending as the infarct-related artery were the only factors that predicted both angiographic and ECG no-reflow (P=0·017 and P=0·02 for EPO; P0·05 for left anterior descending artery, respectively). Conclusions We found an independent, graded, inverse relation between endogenous EPO levels and angiographic and ECG no-reflow following PPCI. In animal models of ischaemia, EPO has been found to be protective. In humans, endogenous EPO may contribute to offset the mechanisms responsible for no-reflow.
AB - Background In models of acute ischaemia, erythropoietin (EPO) administration has been found to attenuate vascular injury largely through reduced apoptosis, suppressed inflammation and increased nitric oxide availability. We studied the association between circulating endogenous EPO and no-reflow in patients with first ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods Blood sampling was performed before PPCI. Consecutive patients with (n=24) or without (n=24) evidence of angiographic no-reflow after PPCI were enrolled. Angiographic no-reflow was defined as Thrombolysis in Myocardial Infarction (TIMI) flow ≤2 or as TIMI flow=3 but with myocardial blush grade -1, P=0·001, and 4·0 (0·6-7·1) vs. 9·3 (1·0-12·6) mIUmL -1, P=0·01, respectively]. At multivariable analysis, decreasing EPO tertiles and left anterior descending as the infarct-related artery were the only factors that predicted both angiographic and ECG no-reflow (P=0·017 and P=0·02 for EPO; P0·05 for left anterior descending artery, respectively). Conclusions We found an independent, graded, inverse relation between endogenous EPO levels and angiographic and ECG no-reflow following PPCI. In animal models of ischaemia, EPO has been found to be protective. In humans, endogenous EPO may contribute to offset the mechanisms responsible for no-reflow.
KW - Acute myocardial infarction
KW - Erythropoietin
KW - No-reflow
KW - Primary PCI
UR - http://www.scopus.com/inward/record.url?scp=80052686712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052686712&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2362.2011.02528.x
DO - 10.1111/j.1365-2362.2011.02528.x
M3 - Article
C2 - 21492156
AN - SCOPUS:80052686712
VL - 41
SP - 1210
EP - 1219
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
SN - 0014-2972
IS - 11
ER -